來寶網Logo

熱門詞:生物顯微鏡 水質分析儀 微波消解 熒光定量PCR 電化學工作站 生物安全柜

現在位置首頁>技術資料首頁>行業動態>公司動態>Takeda同意收購 Intellikine

Takeda同意收購 Intellikine

Takeda2011年12月22日 13:53 點擊:2138



日本武田藥品(Takeda Pharmaceutical)


Takeda同意收購 Intellikine,價格為1.9億美元的哦前期款加上1.2億美元的里程金。此次收購使Takeda獲得了Intellikine的抑制PI3激酶通路的小分子癌癥藥物,其中INK218和INK1117是最有希望的藥物。

 

Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline

Osaka, Japan, December 21, 2011, and La Jolla, California, December 20, 2011 - Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) and Intellikine, Inc. (“Intellikine”) today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

Intellikine has assembled a portfolio of proprietary small molecule kinase inhibitors that selectively target isoforms of the phosphoinositide-3 kinase / mammalian target of rapamycin (PI3K1/mTOR2) pathway. The assets of the company include ongoing Phase 1 clinical programs involving selective inhibition of mTOR kinase and isoform-specific inhibition of PI3Kα, as well as a partnered program involving research and development of isoform-specific inhibitors of PI3Kγ/δ, and a robust discovery research platform in small molecule kinase inhibitors. Intellikine’s most advanced drug candidate, INK128, a novel mTORC1/2 inhibitor, has generated encouraging data in multiple Phase 1 studies and is expected to enter Phase 2 studies in 2012. INK1117, a novel and selective inhibitor of the PI3Kα isoform, entered human clinical testing in September 2011.

Millennium: The Takeda Oncology Company, Takeda’s business unit responsible for global oncology strategy and development, will have global development responsibility for INK128 and INK1117.

“INK128 and INK1117 are potential best-in-class inhibitors of critical pathways driving cancer cell growth,” said Deborah Dunsire, M.D., President and CEO, Millennium. “As single agents or in different combinations with novel molecules within our robust pipeline, we anticipate that these assets will be able to deliver transforming therapies to cancer patients.”

“Intellikine has advanced three programs against the PI3K/mTOR pathway into human clinical testing in just four years,” added Troy Wilson, Ph.D., J.D., President and CEO, Intellikine. “We are pleased that Takeda recognizes the potential of our clinical-stage programs as well as our strong pipeline and discovery engine. Together, with Millennium and Takeda, we can bring the resources and expertise necessary to enable our drug candidates to reach their full potential in the treatment of patients with cancer.”

Intellikine's exclusive financial advisor for the transaction was Lazard while Cooley LLP was its legal advisor. Takeda was represented by Covington & Burling LLP.

Takeda does not expect to revise earnings guidance for its 2011 fiscal year in connection with this acquisition.

  • 1 Phosphatidylinositol 3-kinases (PI 3-kinases or PI3Ks) are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.
  • 2 The mammalian target of rapamycin (mTOR) is a key kinase that regulates many cellular processes including proliferation, protein synthesis, cellular metabolism.
About Intellikine

Intellikine is a leading private company focused on the development of innovative, small molecule drugs targeting the PI3K/mTOR pathway for the treatment of cancer and other serious diseases. Founded in September 2007, Intellikine has raised $41 million from a group of leading investors, including Sofinnova

Ventures, CMEA Capital, Novartis Venture Funds, Abingworth, U.S. Venture Partners, Fintech Global Capital and Biogen Idec.

  • (1) Corporate Name: Intellikine, Inc.
  • (2) Location: La Jolla CA
  • (3) Representative: Troy Wilson, Ph.D., J.D., President and Chief Executive Officer
  • (4) Year of establishment: 2007
  • (5) Capital stock: Raised $41M from a group of leading investors, including Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, Abingworth, U.S. Venture Partners, Fintech Global Capital and Biogen Idec.
  • (6) Shares: Non-listed
  • (7) Number of employees: 36 total
  • (8) Relationship with Takeda: no matters to report regarding capital, personal and transactional relationship with Takeda
About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com.

(來源: Takeda )


全年征稿 / 資訊合作

聯系郵箱:[email protected]

版權與免責聲明

  • 凡本網注明“來源:來寶網”的所有作品,版權均屬于來寶網,轉載請必須注明來寶網, http://www.vhyrck.live,違反者本網將追究相關法律責任。
  • 本網轉載并注明自其它來源的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點或證實其內容的真實性,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品來源,并自負版權等法律責任。
  • 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。


35选7开奖查询